Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need ...

Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...

It's exactly seven years since Liverpool nailed their colours to the mast as a genuine contender for the Champions League.In ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...